EDB-102
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for EDB-102, covering 2026-03-10 to 2026-03-10. Get the full timeline:
Most recent: Clinical Trial Update: An Open-Label, Single-Arm, Dose-Escalation Phase I Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of EDB-102 in Patients With EGFR L858R-Mutant, Third-Generation TKI-Resistant Advanced Non-Small Cell Lung Cancer With Liver Metastases [Phase 1]